Sarepta Therapeutics Stock
Sarepta Therapeutics Stock
The price for the Sarepta Therapeutics stock decreased slightly today. Compared to yesterday there is a change of -€0.700 (-0.570%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Sarepta Therapeutics stock is not clear.
As a result the target price of 130 € shows a slightly positive potential of 6.25% compared to the current price of 122.35 € for Sarepta Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Sarepta Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Sarepta Therapeutics in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sarepta Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | -0.570% | 0.493% | 5.157% | 7.043% | 38.280% | 97.594% | 17.351% |
| Exact Sciences | -8.490% | -10.946% | -26.502% | -22.383% | -26.631% | -41.440% | -43.013% |
| Incyte Corp. | -0.940% | -0.162% | -3.022% | -16.379% | -12.901% | -27.345% | -31.910% |
| Regeneron Pharmaceuticals Inc. | 0.900% | 2.813% | 3.405% | 30.574% | 12.727% | 120.343% | 210.000% |
Comments
News
Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q1 2024 Earnings CallMay 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com
1 Top Growth Stock to Buy and Hold for 10 Years
A lot will change in the next 10 years, but our need for innovative medicines is unlikely to be one of them. That's one thing that makes some biotech companies exciting long-term investment
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making